|[January 31, 2013]
Bulletin from Extraordinary General Meeting of Diamyd Medical AB
STOCKHOLM --(Business Wire)--
At the Extraordinary General Meeting of Diamyd Medical AB (publ) held
today, none of the proposals regarding reduction of the share capital
for repayment to shareholders reached the required majority pursuant to
the Companies Act. As a consequence, the proposal regarding stock
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of
pharmaceutical development. Diamyd Medical is headquartered in
Stockholm, Sweden. The Company's development project consists of the
protein GAD for the treatment and prevention of autoimmune diabetes. A
Swedish researcher-initiated Phase II study is ongoing to evaluate
whether GAD can prevent type 1 diabetes in children who are at high risk
o developing the disease.
Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation
(USA) and the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by
the Pink OTC Markets and the Bank of New York Mellon (PAL). Further
information is available on the Company's website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.
Diamyd Medical AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone (News - Alert): +46 8 661 00 26,
Fax: +46 8 661 63 68 E-mail: firstname.lastname@example.org.
Reg. no: 556530-1420
This information was brought to you by Cision http://www.cisionwire.com
[ Back To Cloud Computing 's Homepage ]